Key Clinical Points Postmenopausal Osteoporosis Fragility fractures are very common
among postmenopausal women and are associated with increased morbidity, mortality, and …

The fully human monoclonal antibody denosumab was approved for treatment of
osteoporosis in 2010 on the basis of its potent antiresorptive activity, which produces …

Background No clinical trials have compared osteoporosis drugs with incident fractures as
the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate …

The adult skeleton is renewed by remodeling throughout life. Bone remodeling is a process
where osteoclasts and osteoblasts work sequentially in the same bone remodeling unit …

Background Unlike most chronic diseases, osteoporosis treatments are generally limited to
a single drug at a fixed dose and frequency. Nonetheless, no approved therapy is able to …

In the beginning, that is from the 1960's, when a link between menopause and osteoporosis
was first identified; estrogen treatment was the standard for preventing bone loss, however …

Highlights•Parathyroid hormone has dual anabolic and catabolic actions on the
skeleton.•The OPG–RANKL–RANK pathway is the main mediator of the catabolic actions of …

BACKGROUND Disorders of bone metabolism, most notably osteoporosis, are highly
prevalent and predispose to fractures, causing high patient morbidity and mortality …

As the only cells definitively shown to degrade bone, osteoclasts are key mediators of
skeletal diseases including osteoporosis. Bone-forming osteoblasts, and hematopoietic and …

Background Osteoporosis affects mostly postmenopausal women, leading to deterioration of
the microarchitectural bone structure and low bone mass, with an increased fracture risk with …